LEGION™ Revision Metal Hypersensitivity Study
Status: | Withdrawn |
---|---|
Conditions: | Neurology |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | Any |
Updated: | 4/21/2016 |
Start Date: | January 2016 |
End Date: | April 2025 |
A Prospective, Randomized, Multi-Center, Metal Hypersensitivity Study Comparing OXINIUM and Cobalt Chrome Femoral Components in Failed Total Knee Arthroplasty
This is a prospective, randomized, multi-center, metal hypersensitivity study comparing
OXINIUM and cobalt chrome femoral components in subjects with failed total knee arthroplasty
(TKA).
OXINIUM and cobalt chrome femoral components in subjects with failed total knee arthroplasty
(TKA).
A total of 230 subjects will be randomized (1:1) to receive either an OXINIUM or cobalt
chrome femoral components as part of their LEGION revision procedure. The objective of this
study is to assess a lower serum metal ion concentration level in at least one of the three
major mLTTs (Co, Cr or Ni) over 5 years in subjects receiving OXINIUM versus Cobalt Chrome
femoral components as part of the LEGION Revision Total Knee System.
chrome femoral components as part of their LEGION revision procedure. The objective of this
study is to assess a lower serum metal ion concentration level in at least one of the three
major mLTTs (Co, Cr or Ni) over 5 years in subjects receiving OXINIUM versus Cobalt Chrome
femoral components as part of the LEGION Revision Total Knee System.
Inclusion Criteria:
- Subject is skeletally mature
- Subject is willing to sign and date an IRB/EC approved consent form
- Subject is a candidate for a revision knee replacement
- Subject has met an acceptable preoperative medical clearance and is free or treated
for cardiac, pulmonary, hematological, infection, or other conditions that would pose
excessive operative risk
- Subject agrees to adhere to the 10-year study visit schedule
Exclusion Criteria:
- Subject with a known metal hypersensitivity
- Subject requires a known bilateral revision TKA
- Subject has severe pronation of the ipsilateral foot or any other relevant clinical
condition contributing to abnormal ambulation
- Subject has active infection or sepsis (treated or untreated)
- Subject with an immunosuppressive disorder
- Subject has presence of malignant tumor, metastatic, or neoplastic disease
- Subject has conditions that may interfere with the TKA survival or outcome (i.e.,
Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled
diabetes, moderate to severe renal insufficiency or neuromuscular disease)
- Subject has had intra-articular corticosteroid therapy (or any other intra-articular
therapy) in the study knee within 3 months of study enrollment
- Subject has inadequate bone stock to support the device and would require significant
augmentation to correct the joint Female subject is of child-bearing age and
unwilling to use an approved method of contraception
- Subject has an emotional or neurological condition that would pre-empt their ability
or willingness to comply with the study
- Subject is severely overweight (BMI>40)
- Subject is currently enrolled in another investigational drug, biologic, or device
study or has been treated with an investigational product in the past 30 days
- Subject is facing current or impending incarceration
We found this trial at
3
sites
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials